



ORIGINAL ARTICLE

Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: A prospective multicenter study



M.L. Cantón-Bulnes^{a,*}, M. Jiménez-Sánchez^b, S. Alcántara-Carmona^c,
R. Gimeno-Costa^d, J.Á. Berezo-García^e, C. Beato^f, F. Álvarez-Lerma^g, S. Mojal^h,
P. Olaecheaⁱ, F. Gordo-Vidal^{j,k}, J. Garnacho-Montero^a

^a Intensive Care Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain

^b Intensive Care Clinical Unit, Hospital Universitario Virgen de Rocío, Seville, Spain

^c Intensive Care Unit, Hospital Universitario Puerta de Hierro, Madrid, Spain

^d Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain

^e Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain

^f Medical Oncology Department, Hospital Universitario Virgen de la Macarena, Seville, Spain

^g Intensive Care Unit, Hospital del Mar – Parc de Salut Mar, Barcelona, Spain

^h Bioestadístico, Barcelona, Spain

ⁱ Hospital Universitario Galdakao-Usansolo, Biocruces Bizkaia Health Research Institute, Galdácano, Vizcaya, Spain

^j Intensive Care Unit, Hospital Universitario del Henares, Coslada, Madrid, Spain

^k Grupo de Investigación en Patología Crítica, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain

Received 5 March 2021; accepted 7 August 2021

Available online 16 October 2021

KEYWORDS

Mortality;
Solid cancers;
Hematological malignancy;
Intensive Care Unit;
Mechanical ventilation;
Neutropenia

Abstract

Objectives: To analyze clinical features associated to mortality in oncological patients with unplanned admission to the Intensive Care Unit (ICU), and to determine whether such risk factors differ between patients with solid tumors and those with hematological malignancies.

Design: An observational study was carried out.

Setting: A total of 123 Intensive Care Units across Spain.

Patients: All cancer patients with unscheduled admission due to acute illness related to the background oncological disease.

Interventions: None.

Main variables: Demographic parameters, severity scores and clinical condition were assessed, and mortality was analyzed. Multivariate binary logistic regression analysis was performed.

Results: A total of 482 patients were included: solid cancer ($n = 311$) and hematological malignancy ($n = 171$). Multivariate regression analysis showed the factors independently associated

* Corresponding author.

E-mail address: mluisa.cantonb@gmail.com (M.L. Cantón-Bulnes).

to ICU mortality to be the APACHE II score (OR 1.102; 95% CI 1.064–1.143), medical admission (OR 3.587; 95% CI 1.327–9.701), lung cancer (OR 2.98; 95% CI 1.48–5.99) and mechanical ventilation after the first 24 h of ICU stay (OR 2.27; 95% CI 1.09–4.73), whereas no need for mechanical ventilation was identified as a protective factor (OR 0.15; 95% CI 0.09–0.28). In solid cancer patients, the APACHE II score, medical admission, antibiotics in the previous 48 h and lung cancer were identified as independent mortality indicators, while no need for mechanical ventilation was identified as a protective factor. In the multivariate analysis, the APACHE II score and mechanical ventilation after 24 h of ICU stay were independently associated to mortality in hematological cancer patients, while no need for mechanical ventilation was identified as a protective factor. Neutropenia was not identified as an independent mortality predictor in either the total cohort or in the two subgroups.

Conclusions: The risk factors associated to mortality did not differ significantly between patients with solid cancers and those with hematological malignancies. Delayed intubation in patients requiring mechanical ventilation might be associated to ICU mortality.

© 2021 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

PALABRAS CLAVE

Mortalidad;
Tumores sólidos;
Neoplasia hemática
maligna;
Unidades de Cuidados
Intensivos;
Ventilación
mecánica;
Neutropenia

Factores determinantes de la mortalidad en pacientes con cáncer ingresados de forma no programada en la Unidad de Cuidados Intensivos: estudio multicéntrico prospectivo

Resumen

Objetivos: Determinar las características clínicas asociadas con la mortalidad en pacientes oncológicos ingresados de forma no programada en la UCI. También evaluamos si estos factores de riesgos difieren en los pacientes con neoplasias hematológicas o tumores sólidos.

Diseño: Estudio observacional.

Ámbito: Ciento veintitrés Unidades de Cuidados Intensivos en España.

Pacientes: Todos los pacientes con cáncer ingresados de forma no programada debido a una enfermedad aguda asociada con la enfermedad oncológica.

Intervenciones: Ninguna.

Variables principales: Las variables analizadas fueron los datos demográficos, escalas pronósticas de gravedad y el estado clínico del paciente. Se analizó la mortalidad y los factores relacionados con ésta. Se aplicó un análisis de regresión logística binaria multivariante.

Resultados: Se incluyó a un total de 482 pacientes: con tumores sólidos (n = 331) y con neoplasias hematológicas (n = 171). En el análisis de regresión multivariante, los factores asociados de manera independiente con la mortalidad en la UCI fueron la puntuación APACHE II (OR 1,102; IC del 95% 1,064-1,143), el ingreso médico (OR 3,587; IC del 95% 1,327-9,701), el cáncer de pulmón (OR 2,98, IC del 95% 1,48-5,99) y la ventilación mecánica tras las primeras 24 h de ingreso en la UCI (OR 2,27; IC del 95% 1,09-4,73), mientras que la no necesidad de ventilación mecánica fue un factor protector (OR 0,15; IC del 95% 0,09-0,28). En el caso de los tumores sólidos, la puntuación APACHE II, el ingreso médico, la administración de antibióticos en las 48 h previas y el cáncer de pulmón fueron variables independientes relacionadas con la mortalidad, y la no necesidad de ventilación mecánica se identificó como un factor protector. En el análisis multivariante, la puntuación APACHE II y la ventilación mecánica al cabo de 24 h desde el ingreso en la UCI se asociaron de manera independiente con mortalidad en pacientes con neoplasias hematológicas, mientras que la ausencia de necesidad de ventilación mecánica se consideró como un factor protector. La neutropenia no se identificó con un factor independiente de predicción de mortalidad en la cohorte total de los dos subgrupos.

Conclusiones: Los factores de riesgo asociados a mortalidad no difiere significativamente en pacientes con tumores sólidos o neoplasias hemáticas. El retraso de la intubación en los pacientes que requieren ventilación mecánica podría estar asociado con la mortalidad en la UCI.

© 2021 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

Introduction

Not unfrequently, oncological patients need admission to the ICU. A retrospective multicenter Dutch study showed that 6.4% of cancer patients required ICU admission, revealing that the majority of these admissions took place after surgical procedures.¹ In another retrospective study, 5.2% of the patients required ICU admission within the first 2 years of cancer diagnosis.²

The majority of the oncological patients are admitted for immediate postoperative care and commonly present a low mortality rate.³ Moreover, in the last decade, the number of unscheduled admissions to the ICU by acute medical conditions related to the cancer has risen considerably worldwide. Improvements in short- and long-term survival rates of these cancer patients have been documented explaining this widespread reality.⁴ The advent of new targeted therapies and the enhancement of supportive care justify this increment in ICU admissions even in patients with advanced diseases.

Despite these progresses, death rates of oncology patients in the ICU remain substantially high. Therefore, the identification of prognostic factors in critically ill patients is essential. The understanding of factors associated with poor outcome in this high-risk population may assist physicians, patients, and their relatives in deciding treatment options and their intensity.

In the ICU, patients with hematologic malignancies have higher mortality rates than solid cancer patients.⁵ However, literature is equivocal whether risk factors for mortality differ in patients with solid or hematological malignancies.^{6,7} In fact, these two populations have been considered significantly different.⁸ The presence of neutropenia has been associated with a dismal prognosis in cancer and many clinicians are reluctant to admit patients with severe neutropenia in the ICU. However, if neutropenia influences the outcomes of cancer patients in the ICU and whether this influence differs between solid and hematología malignancies is an ongoing debate.^{9–11}

The aims of this study are to identify the risk factors for mortality of oncological patients admitted to the ICU and to perform specific analyses for solid cancers and for hematological malignancy patients in order to determine if these factors are different for the two populations.

Methods

Prospective observational study carried out in Spanish ICUs using the ENVIN (National Nosocomial Infection Surveillance Study; Estudio Nacional de Vigilancia de Infección Nosocomial in Spanish) registry. It is an observational, prospective and multicenter (national) project that was started in 1994 by the Study Group of Infectious Diseases and Sepsis (GTEIS) of SEMICYUC. It is performed yearly since April 1st to June 30th. Its objectives have been described in detail elsewhere.¹² Data entry is done through a webpage (<http://hws.vhebron.net/envin-helics/>). The ENVIN registry has been approved by several local and regional Clinical Research Ethics Committees and the specific authorization of patients for data collection is not required, as it is

recognized as a Registry of national interest for the National Health System (year 2014).

In 2018, an extension of cancer patient data was carried out associating a new database called ‘‘ONCOENVIN database’’. Adult patients (≥ 18 years) with a clinically confirmed hematologic or solid malignancy admitted to any of the participating ICUs for more than 24 h during the three months of the ENVIN registry were included in this study. In the present manuscript, we report exclusively those patients with an unplanned admission due to an acute medical or surgical condition related to the cancer. We excluded patients who were admitted to the ICU for acute conditions not related to their oncological disease (i.e. trauma, acute coronary syndrome, ...) and patients admitted after elective surgery.

Variables collected at ICU admission were age, gender, severity of illness assessed by APACHE II score in the first 24 h in the ICU, underlying comorbidities, history of surgery within 30 days prior to admission, use of antibiotics in the previous 48 h, type of cancer, year of diagnosis, hospital size (less than 200 beds, 200–500, and more than 500 beds), cancer treatments (no treatment, neoadjuvant chemotherapy, adjuvant chemotherapy, first-line and second-line chemotherapy, symptomatic treatment, chemotherapy for hematological malignancy, allogeneic bone marrow transplantation, and autologous bone marrow transplantation), and length of hospital stay before ICU admission. Solid cancers were grouped into nine categories (see footnotes in Table 4 for details). Hematologic malignancies were categorized as: acute leukemia, chronic leukemia, lymphoma, multiple myeloma, and others. Based on their primary reason for admission to the ICU, patients were categorized in the following groups: sepsis/septic shock following Sepsis-3 definitions, acute respiratory failure, renal failure, coma, hemorrhagic shock, severe metabolic disturbances, or others.

During the ICU stay, details regarding the need for invasive mechanical ventilation, renal replacement therapy, development of neutropenia (neutrophils $< 500/\text{mm}^3$), development of ICU-acquired infection (catheter-related bloodstream infection, ventilator-associated pneumonia, pulmonary aspergillosis), administration of chemotherapy in the ICU, and tumor lysis syndrome¹³ were collected daily. Diagnosis of pulmonary aspergillosis required host risk factors, suggestive signs of fungal infection on CT scan as well as isolation of *Aspergillus* spp. in respiratory culture or Galactomannan antigen detection in serum or bronchoalveolar lavage with a significant optical density index.¹⁴ All patients were followed up until death or ICU discharge.

Statistical analysis

A descriptive analysis was conducted. Categorical variables were summarized with frequencies and percentages, while quantitative variables were described with mean and standard deviation or median (interquartile range) as appropriate. To compare survivors vs non-survivors of the three groups (total cohort, patients with solid malignancy, and patients with hematological malignancy) a bivariate analysis was performed. Chi-square test or Fisher exact test were used according to application conditions for the

categorical variables and Mann–Whitney U test was used for quantitative variables. For every group, the significant and marginally significant variables ($p < 0.1$) obtained in the bivariate analysis and the variables considered clinically relevant, were introduced in a multivariate binary logistic regression analysis in order to assess the factors related to death in the ICU. We considered the “Mechanical ventilation in the first 24 h of ICU admission” category as the reference and it was compared with the two others (“No mechanical ventilation” and “Mechanical ventilation after 24 h of ICU admission”). Variables without statistical significance in the model were subsequently manually removed in a backward step-by-step procedure, until the best possible model was obtained, showing adjusted odds ratio with their 95% confidence intervals and p -values for each of the final variables. Calibration and discrimination power of the model were assessed with Hosmer–Lemeshow test and area under the curve (AUC) respectively. In all analyses, p -values less than 0.05 were considered as statistically significant.

Results

During the study period, 123 Spanish ICUs included oncological patients in the registry. Overall, 2557 cancer patients were admitted to the participating ICUs. Of them, 1506 were scheduled post-operative care, 567 required ICU admission for acute conditions not related to their oncological disease, and 484 patients had an unplanned ICU admission for an acute medical or surgical illness related to a solid or a hematological malignancy. Two of these 484 patients were excluded from the analysis for incomplete data. Therefore, 482 patients comprise the study group of this research. The diagnosis of cancer had been made in 120 patients (24.9%) in the year 2017 or from January to June 2018 in 287 patients (59.5%).

Table 1 depicts the comparison between those patients who were discharged alive from the ICU and those who died in the Unit (mortality rate 29.5%). Of note, age was not statistically different in those who died compared to those who were discharged alive from the ICU. The most common indications for ICU admission were sepsis ($n = 180$) and respiratory insufficiency ($n = 179$). Length of hospital stay before ICU admission was significantly shorter in patients who survived. Hospital bed size did not affect mortality in the total cohort or in the two subgroups. Overall, 215 patients (44.6%) required invasive mechanical ventilation, 156 in the first 24 h in the ICU. The overall mortality rate was 49.8% among patients receiving invasive mechanical ventilation. Mortality rate was greater (p test of Fisher = 0.0478) in those patients on mechanical ventilation in the first 24 h compared to those intubated on day two and onwards (45.5% vs 61%). By multivariate logistic regression analysis, factors independently associated with mortality were APACHE II, medical admission, lung cancer, and mechanical ventilation after 24 h of ICU admission whereas no need of mechanical ventilation was a protective factor (Table 2). Fig. 1 shows the number of deaths for the different subgroups of patients depending on the day of invasive mechanical ventilation onset. The demographics data and clinical features of those patients intubated in the first 24 h in the ICU ($n = 156$; mortality rate

45.5%) compared with those intubated on day 2 and onward ($n = 59$; mortality rate 61%) is shown in Table 3.

To better understand whether these risk factors differ between patients with solid cancer ($n = 311$) and hematological malignancies ($n = 171$), we analyzed these two cohorts separately. Patients with hematological cancer were younger [61 years (51–70) vs 64 years (55–71); $p = 0.046$] and with higher APACHE II score [20 (15–25) vs 17 (12–23); $p = 0.007$] than those with solid cancer. Length of hospital stay before ICU admission was significantly shorter in patients with solid tumor [1 day (0–4) vs 4 days (0–16); $p < 0.001$]. Length of ICU stay was not statistically different in both groups: 5 days^{3–9} for subjects with solid cancer vs 6 days^{4–11} for hematological patients ($p = 0.056$).

Neutropenia at admission to the ICU was significantly more common in hematological patients than in solid tumors (36.8% vs 9.9%; $p < 0.0001$). The rate of patients requiring invasive mechanical ventilation was similar in these two groups: 45.6% vs 44%. Chemotherapy was more frequently administered in the ICU in hematological than in solid tumor patients (15.8% vs 2.25%; $p < 0.001$). Mortality was not statistically different in these two groups of patients: 51.8% vs 36.4% ($p = 0.072$).

Table 4 shows the comparison between survivors and non-survivors in patients with solid cancer. The commonest solid malignancy was lung cancer (25.7%) followed by colon (14.8%) and urologic (13.8%) cancers. Mortality was significantly higher in patients with lung cancer than in patients with other solid malignancies (40% vs 22%; $p = 0.0017$). Urological and gynecological cancers presented the lowest mortality rate (16.6 and 18.7%, respectively). Only 7 patients received chemotherapy in the ICU (4 survived). The multivariate logistic regression analysis identified five factors as independently associated with mortality and another (no need of mechanical ventilation) was a protective variable (Table 2).

Lymphoma was the commonest hematological malignant disease in our series and the great majority of hematological patients had a medical cause of ICU admission (Table 5). Twenty-seven patients received chemotherapy in the ICU (mortality rate 33%). As expected, allogeneic HSCT (hematopoietic stem cell transplantation) had the highest mortality rate (58.3%). In the multivariate analysis, only APACHE II and mechanical ventilation after 24 h of ICU admission were independently associated with mortality while no need of mechanical ventilation was a protective factor (Table 2). As in the previous analyses, neutropenia was not included in the final model.

Discussion

This prospective and multicenter study has identified several risk factors associated with mortality in cancer patients admitted to the ICU. Clinical features associated with mortality do not significantly differ in solid cancer and in hematological malignancies. It must be highlighted that the initiation of mechanical ventilation after 24 h of ICU admission was linked with higher ICU mortality and this effect was also manifest in hematological patients. On the contrary, no need of mechanical ventilation was a protective variable in the entire cohort and in both subgroups (solid and hematological cancers). The poor prognosis in the ICU

Table 1 Comparison between survivors and non-survivors in the total cohort.

	Survivors (n = 340)	Non-survivors (n = 142)	p
<i>Mean age (yr.) median, IQR</i>	63 (53–70)	64 (54–71)	0.28
<i>Gender (female) n (%)</i>	106 (31.2)	51 (35.9)	0.31
<i>APACHE II median, IQR</i>	17 (12–22)	23 (18–28)	<0.001
<i>Medical admission</i>	268 (78.8)	127 (89.4)	0.006
<i>Length of hospital stay before ICU admission</i>	1 (0–7)	3 (0–15)	<0.001
<i>Underlying conditions</i>			
COPD	37 (10.9)	17 (12)	0.73
Cirrhosis	5 (1.5)	3 (2.1)	0.61
Diabetes mellitus	55 (19.4)	23 (16.2)	0.40
Chronic renal insufficiency	34 (10)	13 (9.2)	0.77
Hypoalbuminemia*	55 (16.2)	30 (21.1)	0.19
Neutropenia at ICU admission	66 (19.4)	23 (16.2)	0.41
Surgery in the previous 30 days	72 (21.2)	15 (10.6)	0.006
Antibiotics in the previous 48 h	157 (46.2)	88 (62)	0.002
<i>Type of cancer</i>			
Solid cancer (except lung)	180 (52.9)	51 (35.9)	
Lung	48 (14.1)	32 (22.5)	0.002
Hematological	112 (32.9)	59 (41.5)	
<i>Status of malignancy</i>			
No treatment	94 (27.6)	38 (26.8)	
Neoadjuvant chemotherapy	29 (8.5)	11 (7.7)	
Adjuvant chemotherapy	41 (12.1)	6 (7.2)	
First line chemotherapy	44 (12.2)	24 (16.9)	
Second and subsequent lines	37 (10.9)	15 (10.6)	0.045
Chemotherapy for acute hematological malignancy	31 (9.1)	19 (13.4)	
HSCT	16 (1.8)	9 (4.9)	
Others	35 (10.3)	10 (7)	
<i>Cause of admission</i>			
Respiratory failure	113 (33.2)	66 (46.5)	
Sepsis	131 (38.5)	49 (34.5)	0.01
Other**	96 (28.2)	27 (19)	
<i>Mechanical ventilation</i>	108 (31.8)	107 (75.4)	<0.001
<i>Onset of mechanical ventilation</i>			
No mechanical ventilation	232 (65.4)	35 (24.6)	
Mechanical ventilation in the first 24 h of admission	85 (25)	71 (50)	<0.001
Mechanical ventilation after 24 h of admission	23 (6.8)	36 (25.4)	
<i>Renal replacement therapy</i>	15 (4.4)	28 (19.7)	<0.001
<i>Total parenteral nutrition</i>	45 (13.2)	23 (16.2)	0.39
<i>ECMO</i>	1 (0.3)	1 (0.7)	0.52
<i>Complications in the ICU</i>			
Primary bacteremia	6 (1.8)	2 (1.4)	1.000
VAP	6 (1.8)	7 (4.9)	0.051
Pulmonary aspergillosis	3 (0.9)	8 (5.6)	0.016
Neutropenia developed in the ICU	58 (17.1)	29 (20.4)	0.386
Tumor lysis syndrome	6 (1.8)	11 (7.7)	0.001


IQR: interquartile range; COPD: chronic obstructive pulmonary disease; ECMO: extracorporeal membrane oxygenation; HSCT: hematopoietic stem cell transplantation; VAP: ventilator-associated pneumonia.

* Hypoalbuminemia: serum albumin at admission below 30 g/L.

** Other causes of admission: hemorrhagic shock: 29; coma: 21; renal failure: 14; metabolic disturbances: 5; others: 54.

Table 2 Logistic regression analyses.

	Adjusted OR (95% CI)	p
Total cohort		
<i>APACHE II score</i>	1.10 (1.06–1.14)	<0.001
<i>Medical admission</i>	3.59 (1.33–9.70)	0.012
<i>Type of cancer</i>		
Solid cancer (except lung)	1	
Lung	2.98 (1.48–5.99)	0.002
Hematological	1.58 (0.88–2.83)	0.12
<i>Mechanical ventilation</i>		
Mechanical ventilation in the first 24 h of admission	1	
Mechanical ventilation after 24 h of admission	2.27 (1.09–4.73)	0.028
No mechanical ventilation	0.15 (0.09–0.28)	<0.001
Patients with solid malignancy		
<i>APACHE II score</i>	1.123 (1.07–1.178)	<0.001
<i>Medical admission</i>	5.37 (1.71–16.81)	0.004
<i>Antibiotics in the previous 48 h</i>	2.36 (1.21–4.62)	0.012
<i>Lung cancer</i>	2.88 (1.42–5.83)	0.003
<i>Mechanical ventilation</i>		
Mechanical ventilation in the first 24 h of admission	1	
Mechanical ventilation after 24 h of admission	1.18 (0.41–3.37)	0.76
No mechanical ventilation	0.17 (0.08–0.35)	<0.001
Patients with hematological malignancy		
<i>APACHE II score</i>	1.08 (1.02–1.14)	<0.001
<i>Mechanical ventilation</i>		
Mechanical ventilation in the first 24 h of admission	1	
Mechanical ventilation after 24 h of admission	4.36 (1.41–13.46)	<0.01
No mechanical ventilation	0.14 (0.05–0.35)	<0.001

**Figure 1** ICU mortality for the different subgroups of patients with cancer depending on the day of invasive mechanical ventilation initiation.

In patients intubated on day 2 and onward, the distribution of survivors/non-survivors is as follows: day 2: 4/6; day 3: 3/4; day 4: 1/4; day 5: 0/2; day 6 and onward: 0/3.

of lung cancer and medical admissions have been confirmed in this study.

The identification of factors associated with mortality will aide physicians to identify cancer patients who are likely to benefit from ICU care, the use of supportive treatments

and the time of their initiation. The majority of the information on the prognosis of patients with cancer patients who are admitted to the ICU derives from retrospective analyses of large databases or from studies carried out in cancer specialized ICUs.

Table 3 Patients' characteristics of those with invasive mechanical ventilation on day 1 of ICU admission compared with those with invasive mechanical ventilation after 24 h in the ICU (day 2 and onward).

	MV within first 24 h of admission (n = 156)	MV after 24 h of admission (n = 59)	p
Mean age (yr.) median, IQR	62 [53–71]	58 [48–66]	0.012
Gender (female) n (%)	51 (32.7%)	20 (33.9%)	0.867
APACHE II median, IQR	22 [16–27]	19 [15–24]	0.045
Medical admission	120 (76.9%)	55 (93.2%)	0.006
Length of hospital stay before ICU admission	5 [2–17]	10 [3–23]	0.154
<i>Underlying conditions</i>			
COPD	19 (12.2%)	8 (13.6%)	0.785
Cirrhosis	3 (1.9%)	1 (1.7%)	1.000
Diabetes mellitus	29 (18.6%)	9 (15.3%)	0.567
Chronic renal insufficiency	16 (10.3%)	6 (10.2%)	0.985
Hypoalbuminemia*	31 (19.9%)	13 (22.0%)	0.726
Neutropenia at ICU admission	28 (17.9%)	15 (25.4%)	0.221
Surgery in the previous 30 days	36 (23.1%)	9 (15.3%)	0.208
Antibiotics in the previous 48 h	72 (46.2%)	41 (69.5%)	0.002
<i>Type of cancer</i>			
Solid cancer (except lung)	84 (53.8%)	22 (37.3%)	0.001
Lung	27 (17.3%)	4 (6.8%)	
Hematological	45 (28.8%)	33 (55.9%)	
<i>Status of malignancy</i>			
No treatment	50 (32.1%)	11 (18.6%)	0.106
Neoadjuvant chemotherapy	10 (6.4%)	6 (10.2%)	
Adjuvant chemotherapy	14 (9.0%)	2 (3.4%)	
First line chemotherapy	25 (16.0%)	12 (20.3%)	
Second and subsequent lines	16 (10.3%)	3 (5.1%)	
Chemotherapy for acute hematological malignancy	14 (9.0%)	10 (16.9%)	
HSCT	5 (3.2%)	5 (8.5%)	
Others	22 (14.1%)	10 (17%)	
<i>Cause of admission</i>			
Respiratory failure	63 (40.4%)	33 (55.9%)	0.105
Sepsis	51 (32.7%)	16 (27.1%)	
Other	42 (26.9%)	10 (16.9%)	
<i>Mechanical ventilation</i>			
Renal replacement therapy	1 (0.6%)	0 (0.0%)	1.000
Total parenteral nutrition	30 (19.2%)	13 (22.0%)	0.647
ECMO	1 (0.6%)	1 (1.7%)	0.474
<i>Complications in the ICU</i>			
Primary bacteremia	5 (3.2%)	2 (3.4%)	1.000
VAP	9 (5.8%)	4 (6.8%)	0.647
Pulmonary aspergillosis	8 (5.1%)	3 (5.2%)	1.000
Neutropenia developed in the ICU	22 (14.1%)	15 (25.4%)	0.050
Tumor lysis syndrome	4 (2.6%)	7 (11.9%)	0.011

IQR: interquartile range; COPD: chronic obstructive pulmonary disease; ECMO: extracorporeal membrane oxygenation; HSCT: hematopoietic stem cell transplantation; VAP: ventilator-associated pneumonia.

* Hypoalbuminemia: serum albumin at admission below 30 g/L.

Approximately, two-thirds of our patients had been previously diagnosed with a solid tumor and the remainings had a malignant hematological disease. This proportion of hematological patients is higher than what has been reported by others,^{4,8} probably reflecting the improvement of the prognosis of these patients. In agreement with previous

investigations, respiratory failure and sepsis are the most common reasons for admission.

In our series, medical cancer patients have 3.5 times higher risk of ICU mortality compared with surgical admissions. In a systematic review,¹⁵ medical cancer patients had an increased risk of ICU mortality between

Table 4 Comparison between survivors and non-survivors in solid cancer patients.

	Survivors (n = 228)	Non-survivors (n = 83)	p
<i>Mean age (yr.) median, IQR</i>	63 (54.5–71)	65 (57–73)	0.10
<i>Gender (female) n (%)</i>	70 (30.7)	30 (36.1)	0.415
<i>APACHE II median, IQR</i>	16 (12–21)	23 (18–28)	<0.001
<i>Medical admission</i>	162 (71.1)	71 (85.5)	0.009
<i>Length of hospital stay before ICU admission</i>	0.5 (0–4)	2 (0–8)	<0.001
<i>Underlying conditions</i>			
COPD	29 (12.7)	12 (14.5)	0.68
Cirrhosis	2 (0.9)	2 (2.4)	0.28
Diabetes mellitus	45 (19.7)	17 (20.5)	0.40
Chronic renal insufficiency	24 (10.5)	9 (10.8)	0.92
Hypoalbuminemia	40 (17.5)	18 (21.7)	0.41
Neutropenia at ICU admission	27 (11.8)	4 (4.8)	0.067
Previous surgery	66 (28.9)	12 (14.5)	0.009
Antibiotics in the previous 48 h	86 (37.7)	42 (50.6)	0.041
<i>Type of cancer</i>			
Solid cancer (except lung)*	180 (78.9)	51 (61.4)	0.002
Lung	48 (21.2)	32 (38.6)	
<i>Status of malignancy</i>			
No treatment	82 (36)	30 (36.1)	0.102
Neoadjuvant chemotherapy	26 (11.4)	7 (8.4)	
Adjuvant chemotherapy	35 (15.4)	6 (7.2)	
First line chemotherapy	26 (10.9)	15 (18.1)	
Second and subsequent lines	28 (12.3)	11 (13.3)	
Others	41 (17.2)	14 (16.8)	
<i>Cause of admission</i>			
Respiratory failure	66 (28.9)	41 (49.4)	0.004
Sepsis	88 (38.6)	23 (27.7)	
Other**	74 (32.5)	19 (22.9)	
<i>Mechanical ventilation</i>	79 (34.6)	58 (69.9)	<0.001
<i>Onset of mechanical ventilation</i>			
No mechanical ventilation	149 (65.4)	25 (30.1)	<0.001
Mechanical ventilation in the first 24 h of admission	64 (28.1)	47 (56.6)	
Mechanical ventilation after 24 h of admission	15 (6.6)	11 (13.1)	
<i>Renal replacement therapy</i>	10 (4.4)	9 (10.8)	0.03
<i>Total parenteral nutrition</i>	33 (14.5)	12 (14.5)	1
<i>ECMO</i>	0 (0)	1 (1.2)	0.1
<i>Complications in the ICU</i>			
Primary bacteremia	6 (1.8)	2 (2.4)	0.91
VAP	6 (1.8)	7 (4.9)	0.051
Pulmonary aspergillosis	1 (0.4)	5 (6)	0.01
Neutropenia developed in the ICU	25 (11)	4 (4.8)	0.099
Tumor lysis syndrome	2 (0.9)	2 (2.4)	0.289

IQR: interquartile range; COPD: chronic obstructive pulmonary disease; ECMO: extracorporeal membrane oxygenation.

* Head and neck (n = 32), colon (n = 46), liver, biliary duct and pancreas (n = 20), other digestive cancer (n = 22), kidney-urinary tract (n = 43), gynecological (n = 32), central nervous system (n = 18), and others (n = 18).

** Other causes of admission: hemorrhagic shock: 26; coma: 14; renal failure: 10; metabolic disturbances: 2; others: 41.

two- to fourfold compared to surgical patients. Of note, medical admission was not a variable associated with mortality in hematological patients. This can be explained by the fact that less than 5% of these patients had a surgical reason for ICU admission. As expected, severity of illness measured by APACHE II score is associated with greater risks

of mortality as generally occurs in previous studies.¹⁵ In our data, each point of increment contributes to a 10% increase in the risk of death.

Lung cancer is the commonest tumor type admitted to the ICU and the one with the poorest outcome.¹⁵ Lung cancer patients may benefit less from ICU admission than

Table 5 Hematological malignancies: Comparison between survivors and non-survivors.

	Survivors (n = 112)	Non-survivors (n = 59)	p
<i>Mean age (yr.) median, IQR</i>	62 (51–70)	62 (52–69)	0.91
<i>Gender (female) n (%)</i>	36 (32.1)	21 (35.6)	0.65
<i>APACHE II median, IQR</i>	19 (13–23)	22 (19–27)	<0.001
<i>Medical admission</i>	106 (94.4)	56 (94.9)	0.94
<i>Length of hospital stay before ICU admission</i>	3 (0–14)	7 (1–18)	0.14
<i>Underlying conditions</i>			
COPD	8 (7.1)	5 (8.5)	0.75
Cirrhosis	3 (2.7)	1 (1.7)	0.69
Diabetes mellitus	21 (18.8)	6 (10.2)	0.14
Chronic renal insufficiency	24 (10.5)	9 (10.8)	0.92
Neutropenia at ICU admission	39 (34.8)	24 (40.7)	0.45
Previous surgery	6 (5.4)	3 (5.1)	0.94
<i>Type of cancer</i>			
Acute leukemia	36 (32.1)	24 (40.7)	0.174
Lymphoma	45 (40.2)	26 (40.1)	
Other	31 (27.7)	9 (15.3)	
<i>Status of malignancy</i>			
No treatment	12 (10.7)	8 (13.6)	0.239
Chemotherapy	86 (76.8)	42 (71.2)	
Allogenic HSCT	5 (4.5)	7 (11.9)	
Autologous HSCT	9 (8)	2 (3.4)	
<i>Cause of admission</i>			
Respiratory failure	47 (42)	25 (42.4)	0.57
Sepsis	43 (38.4)	26 (44.1)	
Other*	22 (19.6)	8 (13.6)	
<i>Mechanical ventilation</i>	29 (25.9)	49 (83.1)	<0.001
<i>Onset of mechanical ventilation</i>			
No mechanical ventilation	83 (74.1)	10 (16.9)	<0.001
Mechanical ventilation in the first 24 h of admission	21 (18.8)	24 (40.7)	
Mechanical ventilation after 24 h of admission	8 (7.1)	25 (42.4)	
<i>Renal replacement therapy</i>	5 (4.5)	19 (32.2)	<0.001
<i>Total parenteral nutrition</i>	12 (10.7)	11 (18.6)	0.149
<i>ECMO</i>	1 (0.9)	0 (0)	0.467
<i>Complications in the ICU</i>			
Primary bacteremia	6 (1.8)	2 (3.4)	0.56
VAP	1 (0.9)	3 (5.1)	0.085
Pulmonary aspergillosis	2 (1.8)	3 (5.1)	0.205
Neutropenia developed in the ICU	33 (29.5)	25 (42.4)	0.099
Tumor lysis syndrome	4 (3.6)	9 (15.3)	0.006

IQR: interquartile range; COPD: chronic obstructive pulmonary disease; ECMO: extracorporeal membrane oxygenation; HSCT: hematopoietic stem cell transplantation.

* Other causes of admission: hemorrhagic shock: 3; coma: 7; renal failure: 4; metabolic disturbances: 3; others: 13.

other types of cancers. Importantly, a recent manuscript has demonstrated that from 2011 to 2019, adjusted mortality in cancer patients requiring ICU admission decreased by 9.2% with lung cancer patients having the lowest reduction.¹⁶

The impact of cancer stage on mortality has been long debated with conflicting results. Diverse studies suggest that advanced or metastatic cancer was associated with

higher ICU or hospital mortality.^{7,17,18} However, very scarce information is available about the impact on the outcome depending on the type of chemotherapy that is administered before ICU admission. Notably, in our data, the type of chemotherapy received, including second line chemotherapy did not influence the ICU mortality. In addition, administration of chemotherapy in the ICU does not impact on ICU mortality although the long-term

prognosis is dismal.¹⁹ In comparison to hematological patients, chemotherapy was unfrequently administered to patients with solid tumors.²⁰

We found that neither neutropenia at admission to the ICU nor its development during the ICU stay increases mortality. It is important to point out that we defined severe neutropenia as a neutrophil count below 500/mm³. A recent meta-analysis on individual data that considered neutropenia as a neutrophil count below 1000/mm³ concluded that neutropenia was independently associated with mortality.¹¹

Mechanical ventilation has been identified as an independent predictor of mortality by previous studies.^{6,8,9,21,22} However, very few information is available about the impact on prognosis of delayed intubation. Inconsistent data have been published regarding the harm or benefit of noninvasive mechanical ventilation (NIV) in these patients. Others have documented that the use of NIV is associated with increased mortality because it delays endotracheal intubation and mechanical ventilation.²³ A recent multicenter study concluded that the need of invasive mechanical ventilation in immunocompromised patients (85% of them with cancer) after NIV or high flow nasal cannula (HFNC) failure, was associated with mortality with higher likelihoods of mortality in case of NIV or HFNC failure.²⁴ Conversely, cancer patients undergoing initial invasive MV had an increased ICU and hospital mortality.²⁵ This discrepancy may in part be explained by differences in the case mix, admission criteria, and treatment protocols.

Our data demonstrate that no intubation in the ICU was an independent protective factor for mortality, observing that mechanical ventilation onset beyond the first day in ICU increased the risk of a fatal outcome compared to those who were intubated in the first 24 h. In other words, the use of prolonged periods to avoid intubation might not be considered the standard of care since this delay is associated with an increased probability of death. In our experience, patients intubated after 24 h in the ICU are younger, with lower APACHE II score, mostly medical patients and with hematological malignancy in comparison with those intubated in the first day. We cannot rule out that in some cases, delayed intubation may have been explained by a poor prognosis of these patients since mechanical ventilation it is recognized as an independent predictor of mortality.

We acknowledge several limitations of this study. First, hospital or long-term mortalities were not recorded in our database admitting their importance in cancer patients. Second, since the use of NIV, HFNC or the reason for intubation were not recorded we cannot explore whether these interventions might have been associated with a higher mortality. Third, failure of organs was not monitored throughout the length of ICU stay. Finally, as this is an observational study, management of patients was not standardized and different treatment protocols were used in the participating units.

Some strengths of our research should also be highlighted. This is a prospective, multicenter study with a relatively large number of patients enrolled, in polyvalent ICUs across Spain and therefore reflecting the real-life situations. All the clinical predictors identified as independently associated with mortality are easily available and may help to identify cancer patients who may not benefit from intensive care or the use of aggressive therapies.

In summary, identifying the determinants of outcomes in critically ill patients with cancer is crucial to improve the use of the ICU avoiding unnecessary advanced life support. The long-held belief about the worse prognosis of cancer patients with neutropenia in the ICU is not supported by our data. Similarly, the type of chemotherapy that the patient is receiving does not influence the short-term outcome. Although the intubation of a critically ill cancer patient is frequently a stressful decision, our data suggest that it should not be delayed because it worsens the patient chance of survival. The prognosis of lung cancer requiring ICU admission is worse than in any other type of cancer including hematological malignancies. All this information may be of aid for clinicians involved in critically ill cancer patient management but larger studies with a longer follow-up are warranted to more precisely define the patient who will benefit from ICU admission optimizing the use of ICU resources.

Funding

None declared.

Conflicts of interest

The authors report no conflicts of interest. JGM and PO are the project coordinators, they designed the study protocol and contacted the researchers. SM has performed statistical analysis. JGM and MLCB have written the contents of the manuscript. All researchers have participated in the inclusion of cases and have reviewed the version of the manuscript.

References

1. Bos MMEM, Verburg IWM, Dumaij I, Stouthard J, Nortier JWR, Richel D, et al. Intensive care admission of cancer patients: a comparative analysis. *Cancer Med.* 2015;4:966–76, <http://dx.doi.org/10.1002/cam4.430>.
2. Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison DS. Risk of critical illness among patients with solid cancers: a population-based observational study. *JAMA Oncol.* 2015;1:1078–85, <http://dx.doi.org/10.1001/jamaoncol.2015.2855>.
3. Olaechea Astigarraga PM, Álvarez Lerma F, Beato Zambrano C, Gimeno Costa R, Gordo Vidal F, Durá Navarro R, et al. Epidemiology and prognosis of patients with a history of cancer admitted to intensive care. A multicenter observational study. *Med Intensiva.* 2020, <http://dx.doi.org/10.1016/j.medin.2020.01.013>.
4. Darmon M, Bourmaud A, Georges Q, Soares M, Jeon K, Oeyen S, et al. Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. *Intensive Care Med.* 2019;45:977–87, <http://dx.doi.org/10.1007/s00134-019-05653-7>.
5. Ostermann M, Ferrando-Vivas P, Gore C, Power S, Harrison D. Characteristics and outcome of cancer patients admitted to the ICU in England, Wales, and Northern Ireland and National Trends between 1997 and 2013. *Crit Care Med.* 2017;45:1668–76, <http://dx.doi.org/10.1097/CCM.0000000000002589>.
6. Staudinger T, Stoiser B, Müllner M, Locker GJ, Laczika K, Knapp S, et al. Outcome and prognostic factors in critically ill cancer patients admitted to the

- intensive care unit. *Crit Care Med.* 2000;28:1322–8, <http://dx.doi.org/10.1097/00003246-200005000-00011>.
7. Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. *J Crit Care.* 2014;29:618–26, <http://dx.doi.org/10.1016/j.jcrc.2014.01.014>.
 8. Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent J-L. Characteristics and outcomes of cancer patients in European ICUs. *Crit Care.* 2009;13:R15, <http://dx.doi.org/10.1186/cc7713>.
 9. Mokart D, Darmon M, Resche-Rigon M, Lemiale V, Pène F, Mayaux J, et al. Prognosis of neutropenic patients admitted to the intensive care unit. *Intensive Care Med.* 2015;41:296–303, <http://dx.doi.org/10.1007/s00134-014-3615-y>.
 10. Bouteloup M, Perinel S, Bourmaud A, Azoulay E, Mokart D, Darmon M, et al. Outcomes in adult critically ill cancer patients with and without neutropenia: a systematic review and meta-analysis of the Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GRRR-OH). *Oncotarget.* 2017;8:1860–70, <http://dx.doi.org/10.18632/oncotarget.12165>.
 11. Georges Q, Azoulay E, Mokart D, Soares M, Jeon K, Oeyen S, et al. Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. *Crit Care.* 2018;22:326, <http://dx.doi.org/10.1186/s13054-018-2076-z>.
 12. Álvarez Lerma F, Olaechea Astigarraga P, Nuvials X, Gimeno R, Catalán M, Gracia Arnillas MP, et al. Is a project needed to prevent urinary tract infection in patients admitted to Spanish ICUs? *Med Intensiva.* 2019;43:63–72, <http://dx.doi.org/10.1016/j.medin.2017.12.003>.
 13. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. *Br J Haematol.* 2004;127:3–11, <http://dx.doi.org/10.1111/j.1365-2141.2004.05094.x>.
 14. Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. *Curr Opin Infect Dis.* 2014;27:174–83, <http://dx.doi.org/10.1097/QCO.000000000000043>.
 15. Puxty K, McLoone P, Quasim T, Kinsella J, Morrison D. Survival in solid cancer patients following intensive care unit admission. *Intensive Care Med.* 2014;40:1409–28, <http://dx.doi.org/10.1007/s00134-014-3471-9>.
 16. Zampieri FG, Romano TG, Salluh JIF, Taniguchi LU, Mendes PV, Nassar AP, et al. Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: a multicenter cohort study. *Intensive Care Med.* 2020, <http://dx.doi.org/10.1007/s00134-020-06184-2>.
 17. Azoulay E, Moreau D, Alberti C, Leleu G, Adrie C, Barbotou M, et al. Predictors of short-term mortality in critically ill patients with solid malignancies. *Intensive Care Med.* 2000;26:1817–23, <http://dx.doi.org/10.1007/s001340051350>.
 18. Caruso P, Ferreira AC, Laurienzo CE, Tittton LN, Terabe DSM, Carnieli DS, et al. Short- and long-term survival of patients with metastatic solid cancer admitted to the intensive care unit: prognostic factors. *Eur J Cancer Care.* 2010;19:260–6, <http://dx.doi.org/10.1111/j.1365-2354.2008.01031.x>.
 19. Zerbib Y, Rabbat A, Fartoukh M, Bigé N, Andréjak C, Mayaux J, et al. Urgent chemotherapy for life-threatening complications related to solid neoplasms. *Crit Care Med.* 2017;45:e640–8, <http://dx.doi.org/10.1097/CCM.0000000000002331>.
 20. Azoulay E, Schellongowski P, Darmon M, Bauer PR, Benoit D, Depuydt P, et al. The Intensive Care Medicine research agenda on critically ill oncology and hematology patients. *Intensive Care Med.* 2017;43:1366–82, <http://dx.doi.org/10.1007/s00134-017-4884-z>.
 21. Al-Zubaidi N, Shehada E, Alshabani K, ZazaDitYafawi J, Kingah P, Soubani AO. Predictors of outcome in patients with hematologic malignancies admitted to the intensive care unit. *Hematol Oncol Stem Cell Ther.* 2018;11:206–18, <http://dx.doi.org/10.1016/j.hemonc.2018.03.003>.
 22. Lemiale V, Pons S, Mirouse A, Tudesq J-J, Hourmant Y, Mokart D, et al. Sepsis and septic shock in patients with malignancies: a Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. *Crit Care Med.* 2020;48:822–9, <http://dx.doi.org/10.1097/CCM.0000000000004322>.
 23. de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kouatchet A, et al. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. *Shock.* 2013;39:250–4, <http://dx.doi.org/10.1097/SHK.0b013e3182866d32>.
 24. Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer PR, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. *Intensive Care Med.* 2017;43:1808–19, <http://dx.doi.org/10.1007/s00134-017-4947-1>.
 25. Azevedo LCP, Caruso P, Silva UVA, Torelly AP, Silva E, Rezende E, et al. Outcomes for patients with cancer admitted to the ICU requiring ventilatory support: results from a prospective multicenter study. *Chest.* 2014;146:257–66, <http://dx.doi.org/10.1378/chest.13-1870>.